[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625945":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":19,"locations":20,"responsibleParty":41,"collaborators":43,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":49,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":19,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":23,"whyStopped":19,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Casa di Cura Dott. Pederzoli","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"non-pharmacological therapy arm","after discharge from the experimental center the subject will be prescribed drug therapy, as directed by the medical experimenter, and non-drug therapy.\n\nFor the next 2 months, in addition to conventional therapy, each individual will be combined with non-pharmacological therapy consisting of essential oils and a post- and prebiotic component.",[12],"Dietary Supplement: Tea tree (Melaleuca alternifolia), Cinnamon (Cynnamomum zeylanicum) bark, Clove carnation (Eugenia caryopyllus) flowers, Red thyme (Thymus vulgaris) plant",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DIETARY_SUPPLEMENT","Tea tree (Melaleuca alternifolia), Cinnamon (Cynnamomum zeylanicum) bark, Clove carnation (Eugenia caryopyllus) flowers, Red thyme (Thymus vulgaris) plant","Patients will take 2 capsules\u002Fday of the product",[9],null,[21],{"facility":22,"status":23,"city":24,"state":25,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Ospedale P. Pederzoli Casa di Cura Privata S.p.A.","RECRUITING","Peschiera del Garda","Verona","37019","Italy","IT",{"type":30,"coordinates":31},"Point",[32,33],10.68614,45.43912,{"lat":33,"lon":32},[36],{"name":37,"role":38,"phone":39,"phoneExt":19,"email":40},"Antonio Fusco, MD","CONTACT","+39 0456444193","urc@ospedalepederzoli.it",{"type":42,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[44],{"name":45,"class":46},"Herboplanet Srl","UNKNOWN","100625945","evaluation-through-innovative-examinations-of-intestinal-dysbiosis-status-in-patients-diagnosed-with-cardiovascular-diseases-and-evaluation-of-the-efficacy-of-natural-and-probiotic-extracts-in-the-non-pharmacological-approach-to-improving-intestinal-dysbiosis-status-100625945",false,"NCT07429227","Evaluation Through Innovative Examinations of Intestinal Dysbiosis Status in Patients Diagnosed With Cardiovascular Diseases and Evaluation of the Efficacy of Natural and Probiotic Extracts in the Non-pharmacological Approach to Improving Intestinal Dysbiosis Status.","Metabolomic and Cellular Inflammaging Investigation Study of Patients With Acute Coronary Syndrome (ACS)","DISBIO","Inclusion Criteria:\n\n* 1\\. Signing of informed consent\n* 2\\. Diagnosis of Acute Coronary Syndrome (ACS)\n* 3\\. Age 30-70\n\nExclusion Criteria:\n\n1. Use in the three months preceding the signing of the informed consent of:\n\n   i) Lipid-lowering drugs containing statins, ezetimibe, fibrates ii) Lipid-lowering nutraceuticals containing monacolin K iii) Monoclonal antibodies that inhibit PCSK9 (proprotein convertase subtilisin\u002Fkexin type 9) such as Evolocumab and Alirocumab\n2. Diagnosis of conditions such as HIV, cancer and diabetes I and II Furthermore, if a female patient becomes pregnant during the trial, this will be one of the reasons for early exit from the study.","ALL","30 Years","70 Years",{"count":59,"type":60},15,"ESTIMATED","INTERVENTIONAL",[63],"NA","The prospective experimental study aims to take an instantaneous photograph of the subject at time T0 and after 24 hours of intestinal permeability and dysbiosis indices in patients with acute coronary syndromes (ACS) which include unstable coronary artery disease (unstable angina) and acute myocardial infarction (AMI). The aim is to verify whether essential oils in particular formulations with high bioavailability are able to re-establish intestinal eubiosis after 2 months, confirmed by tests laboratory specifics such as metabolomics.",[66],"Acute Coronary Syndromes (ACS)",[68,69,70,71,72,73,74],"intestinal permeability","unstable coronary artery disease","acute myocardial infarction","metabolomic","essential oils","dietary supplement","dysbiosis","2026-02-17",{"date":77,"type":78},"2026-02-24","ACTUAL",{"date":80,"type":60},"2026-03",{"date":82,"type":60},"2027-03",{"name":5,"class":6},1]